Glenmark Pharmaceuticals is currently trading at Rs. 906.80, up by 15.90 points or 1.78% from its previous closing of Rs. 890.90 on the BSE.
The scrip opened at Rs. 916.20 and has touched a high and low of Rs. 929.90 and Rs. 900.55 respectively. So far 40,352 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 729.30 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 929.90 and Rs. 877.00 respectively. The current market cap of the company is Rs. 25,591.24 crore.
The promoters holding in the company stood at 46.49%, while Institutions and Non-Institutions held 41.24% and 12.27% respectively.
Glenmark Pharmaceuticals has received the EIR (Establishment Inspection Report) for its Ankleshwar plant. The EIR is issued by the US Food and Drug Administration (USFDA) only if it finds the facility to be deemed acceptable.
The company has recently has received USFDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 study of GSP 304 (tiotropium bromide) for administration by nebulization for the long term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 80 countries. It has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of oncology, respiratory disease, and dermatology.
